<DOC>
	<DOC>NCT00094848</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, efficacy and exposure to TRM-1 in subjects with relapsed or refractory Non-Hodgkin's Lymphoma (NHL).</brief_summary>
	<brief_title>Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Primary Relapsed or refractory histologically confirmed NonHodgkin's Lymphoma Previously treated with at least 1 therapeutic regimen and relapsed or progressed or failed to achieve a response after the last regimen 18 years of age or older Primary Received a nonFDA approved investigational agent within the last 4 weeks Received cancer therapies (chemotherapy, biological therapy [including hormonotherapy], radiation therapy or immunosuppressants within the last 3 weeks, 8 weeks for monoclonal antibodies, radioimmunotherapy or nitrosourea Eligible for a hematopoietic stem cell transplant (HSCT) or have had an autologous HSCT within the last 16 weeks Prior history of an allogeneic HSCT HIV, AIDSrelated lymphoma, central nervous system (CNS) lymphoma, HepatitisB or HepatitisC Infection requiring antibiotics within the last 4 weeks Major surgery within the last 4 weeks Pregnant or breastfeeding women History of other cancers within the past 5 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>